Quality assurance of radiotherapy in the ongoing EORTC 1420 "Best of" trial for early stage oropharyngeal, supraglottic and hypopharyngeal carcinoma: results of the benchmark case procedure. by Stelmes, J-J et al.
Stelmes et al. Radiat Oncol           (2021) 16:81  
https://doi.org/10.1186/s13014-021-01809-2
RESEARCH
Quality assurance of radiotherapy 
in the ongoing EORTC 1420 “Best of” trial 
for early stage oropharyngeal, supraglottic 
and hypopharyngeal carcinoma: results 
of the benchmark case procedure
J‑J Stelmes1*† , E. Vu2†, V. Grégoire3, C. Simon4, E. Clementel5†, J. Kazmierska6, W. Grant7, M. Ozsahin4, 
M. Tomsej8, L. Vieillevigne9, C. Fortpied5, E. C. Hurkmans10, A. Branquinho11, N. Andratschke12, 
F. Zimmermann13 and D.‑C. Weber14,15 
Abstract 
Introduction: The current phase III EORTC 1420 Best‑of trial (NCT02984410) compares the swallowing function after 
transoral surgery versus intensity modulated radiotherapy (RT) in patients with early‑stage carcinoma of the orophar‑
ynx, supraglottis and hypopharynx. We report the analysis of the Benchmark Case (BC) procedures before patient 
recruitment with special attention to dysphagia/aspiration related structures (DARS).
Materials and methods: Submitted RT volumes and plans from participating centers were analyzed and compared 
against the gold‑standard expert delineations and dose distributions. Descriptive analysis of protocol deviations was 
conducted. Mean Sorensen‑Dice similarity index (mDSI) and Hausdorff distance (mHD) were applied to evaluate the 
inter‑observer variability (IOV).
Results: 65% (23/35) of the institutions needed more than one submission to achieve Quality assurance (RTQA) 
clearance. OAR volume delineations were the cause for rejection in 53% (40/76) of cases. IOV could be improved in 5 
out of 12 OARs by more than 10 mm after resubmission (mHD). Despite this, final IOV for critical OARs in delineation 
remained significant among DARS by choosing an aleatory threshold of 0.7 (mDSI) and 15 mm (mHD).
Conclusions: This is to our knowledge the largest BC analysis among Head and neck RTQA programs performed in 
the framework of a prospective trial. Benchmarking identified non‑common OARs and target delineations errors as 
the main source of deviations and IOV could be reduced in a significant number of cases after this process. Due to 
the substantial resources involved with benchmarking, future benchmark analyses should assess fully the impact on 
patients’ clinical outcome.
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Highlights
First BC analysis evaluating delineation of swallowing 
organs, planning volume, and planning variations.
Introduction
Due to the emergence of HPV related oropharyngeal 
cancer and the increase in survival over the past dec-
ades, quality of life and in particular preservation of 
swallowing function becomes of paramount importance 
[1, 2]. Thus, novel strategies such as intensity modu-
lated radiation therapy (IMRT) with defined constraints 
to dysphagia/aspiration related structures (DARS) and 
trans-oral surgery have been developed to provide bet-
ter functional outcome whilst preserving treatment effi-
cacy [3, 4]. A recent randomized phase III trial evaluated 
a dysphagia optimized intensity modulated radiotherapy 
(Do-IMRT) in comparison to a standard IMRT approach: 
The authors could show that a significantly reduced 
dose to the pharyngeal constrictor muscles (PCM) lead 
to an improvement in MDADI scores [5]. However, 
there is a lack of evidence to guide the choice between 
these two treatment options. The EORTC 1420 Best-of 
trial (NCT02984410) has been developed to specifically 
answer the question of functional equivalence between 
these two treatments [6]. The primary endpoint is the 
patient reported swallowing function over the first year 
evaluated by the MD Anderson Dysphagia Inventory [7].
As aberrations of the radiotherapy (RT) protocols can 
influence trial results [8, 9] all EORTC trials involving RT, 
have a dedicated trial specific Quality Assurance (RTQA) 
program [10,11,12] in order to increase validation of the 
results [13, 14].
Thus, as part of such a program, participating institu-
tions are required to submit a benchmark case (BC) prior 
to patient enrollment. Benchmarking assesses sources 
of variation in delineation and treatment planning and 
ensures that the specific delineation and dose/volume 
guidelines for a given trial are correctly understood.
The BC in this trial is based on a selected case which 
fulfills the inclusion criteria of the trial. The RT volumes 
and corresponding reference plan have been created by 
experts in the field of Head and neck cancer (HNC) and 
compared to the single institution (RT volumes and RT 
plan). As swallowing function is the primary endpoint, 
special attention is required in delineating the DARS in 
reference to published guidelines [15].
The aim of this study was to investigate the perfor-
mances of the participating institutions in the trial with 
respect to RT planning and assess the inter-observer 
variability (IOV). Finally, we aimed to evaluate the effec-
tiveness of the BC procedure in reducing IOV across 
participating institutions. To our knowledge, this is the 
largest benchmark case evaluation of a currently ongoing 
phase III HNC trial with a specific dedication to DARS 
variability.
Materials and methods
A case summary including MRI screenshots were sent 
to the institutions. The detailed case description can be 
found as supplemental material. The first step of the exer-
cise consisted of contouring all requested structures of 
the protocol and sending them back for revision. After 
volume approval, the institutions were invited to create a 
treatment plan according to protocol instructions (Chap-
ter  4.5). Three radiation oncologists (J.K; W.G; M.O) 
specialized in head and neck cancer (ROSHNC) as two 
medical physicists (M.T; L.V) were previously elected to 
assess these submissions. Vodca RT software package 
(Visualization and Organization of Data for Cancer Anal-
ysis, Medical Software Solutions GmbH; Hagendorm 
Switzerland) was used for review.
The RTQA experts verified each investigator delinea-
tion and dose planning against a previously defined gold 
standard (GS). In this analysis, GS was made based on 
the following process: First, contouring of the BC was 
done separately by each ROSHNC based on pre-defined 
guidelines [15]. In a second step, a comparison was made, 
and eventual discrepancies discussed during a dedicated 
meeting. This process was repeated until each reviewer 
agreed on every single volume.
Volume definitions and dose prescriptions:
The therapeutic volume included the primary tumor 
and in case of N1 disease the positive lymph node. The 
precise contouring instructions including margins were 
based on current international guidelines [16]. The pro-
phylactic volume included all nodal areas at risk for 
microscopic infiltration in addition to the therapeutic 
volume. Selection of elective lymph node stations were 
based on the publication by Biau et  al. [17]. Unilateral 
irradiation was requested in case the tumor was more 
than 1  cm away from midline. IMRT with a simultane-
ous integrated boost (SIB) was mandatory. Sixty-six and 
or 70 Gy (T2 tumor and N1-node) in 2 Gy per fraction 
with 6 fractions/week was applied to the therapeutic tar-
get volumes. The elective volumes received a total dose 
of 54.45  Gy (T1 Tumor) and 56  Gy (T2 and N1-node) 
respectively. Furthermore, also for organ at risks, clear 
instructions on delineation were specified in the protocol 
[15].
Per protocol every criterion was classified in accept-
able or unacceptable variation according the Global 
Harmonization Group Guidelines [18, 19]. Concise feed-
back was given and in case of unacceptable deviations, 
a resubmission with the needed changes was requested. 
If all parameters were protocol conformal or within 
guidelines-defined limits of acceptability, the benchmark 
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procedure was considered completed. A summary of the 
predefined review criteria can be found in the supple-
mentary material.
Review results by the RTQA experts were collected in 
an Excel spreadsheet and summary statistics about global 
RTQA performance was calculated. Furthermore, in 
order to evaluate IOV, the mean Sørensen-Dice Similar-
ity Index (mDSI) and the mean percentile Hausdorff dis-
tance (mHD) were calculated retrospectively using MIM 
Software Inc, Cleveland, Ohio, USA, Version 6.9.2.The 
mDSI, also called the overlap index, is based upon the 
formula:
with A and B representing the volumes of the contoured 
region of interest performed by the expert and one of the 
institutions, respectively. Values close to 1 indicate simi-
lar contours [20]. The HD measures the largest minimal 
distance between two boundaries. The ideal case with 
perfect superimposition corresponds to a HD equal to 
zero. Means and standard deviations were calculated for 
Dice and HD indexes and means and ranges for doses to 
OARs. Descriptive statistics and plots were generated 
using SAS software (SAS Institute Inc., Cary, NC, USA) 
[21].
Results
Thirty-five centers have participated in the EORTC 1420 
BC analysis. Sixty-five percent (23/35) of them needed 
more than one submission (2, 1–4). In total, the RTQA 
intervention has detected 76 unacceptable deviations. 
Among them, OAR delineations were the cause for 




delineations in 35% (27/76). Lastly, concerning planning 
deviations, non-fulfillment of the given dose-constraints 
was notified in 12% (9/76). However, at a single evalua-
tion, we found that elective volume delineation (pro-
phylactic PTV), resulted as the major cause of rejection 
in 24% (19/76). Among OARs, pharyngeal constrictor 
muscles (PCM) (8/76) were the most frequent organs. 
A detailed table can be found as supplementary mate-
rial. mDSI/mHD indexes between initially rejected and 
finally accepted volumes have been investigated: Con-
cerning mDSI, the differences between the first and last 
submissions were marginal with a mean difference rang-
ing from − 0.01 to 0.20 across all volumes including pro-
phylactic PTV (pPTV) (mDSI difference of 0.07). On the 
other hand, the mean difference in mHD has noteworthy 
improved for almost all RT volumes and were as large as 
− 13.1 mm for the mandible (M) and − 10.8 mm for the 
extended oral cavity (EOC). More precisely, in 5 out of 12 
volumes, the mHD decreased by even more than 10 mm 
including for prophylactic PTV (mHD change: 10.6) 
(Table 1). In addition, a proportional correlation between 
major rejection rate and the subsequent improvement 
in terms of mHD seems plausible. Indeed, pPTV and 
PCM, both figured among the most frequent causes of 
BC rejection and had their mHD improved by more than 
10 mm.
Globally, all volumes confound, final IOV varied 
between 0.33–0.92 and 4.36–22.86 for mDSI and mHD 
(Table  2). Regarding each volume separately, the lowest 
agreement in confront to expert delineations based on the 
mDSI was observed for the cricopharyngeal inlet (CPI), 
the cervical esophagus (CE) and the glottis (G) with a 
mean ± SD of 0.33 ± 0.16, 0.44 ± 0.22 and 0.56 ± 0.20 
respectively. Figure 1 shows a visual representation of the 
Table 1 Comparison of mDSI/mHD index evaluation for initially rejected and finally accepted volumes
Index mDSI (SD) mHD (SD)
Volumes(n = 67) First Final Difference First Final Difference
Planning organ‑at‑risk volume of the brainstem (3) 0.74 (0.16) 0.75 (0.14) 0.01 (0.02) 8.94 (4.26) 7.88 (3.38) − 1.1 (1.1)
Cervical esophagus (4) 0.49 (0.10) 0.33 (0.16) − 0.16 (0.13) 27.22 (11.98) 18.83 (8.44) − 8.4 (14.0)
Cricoid pharyngeal inlet (5) 0.36 (0.22) 0.38 (0.09) 0.03 (0.20) 13.42 (6.75) 13.19 (3.87) − 0.2 (9.6)
Contralateral sub‑mandibular gland (1) 0.83 (.) 0.83(.) 0.00(.) 5.37 (.) 5.37 (.) 0.0 (.)
Extended oral cavity—PTV (5) 0.76 (0.02) 0.84 (0.08) 0.08 (0.06) 26.36 (4.22) 15.56 (9.19) − 10.8 (9.7)
Glottis (3) 0.43 (0.19) 0.56 (0.15) 0.14 (0.34) 13.28 (7.63) 8.58 (4.89) − 4.7 (12.3)
Mandible (6) 0.88 (0.04) 0.91 (0.02) 0.03 (0.03) 19.84 (8.59) 6.75 (4.98) − 13.1 (8.8)
Pharyngeal constrictor muscles (8) 0.47 (0.16) 0.59 (0.09) 0.12 (0.12) 30.34 (8.83) 19.70 (3.65) − 10.6 (8.4)
Prophylactic PTV (19) 0.70 (0.13) 0.78 (0.05) 0.07 (0.13) 26.23 (16.33) 15.64 (4.59) − 10.6 (17.1)
Therapeutic PTV (8) 0.64 (0.15) 0.70 (0.10) 0.06 (0.11) 11.14 (4.05) 10.17 (2.31) − 1.0 (3.7)
Planning organ‑at‑risk volume of the spinal cord (3) 0.78 (0.07) 0.80 (0.09) 0.01 (0.02) 6.61 (2.73) 6.68 (2.80) 0.1 (1.1)
Supraglottic larynx (2) 0.42 (0.31) 0.41 (0.29) − .01 (0.02) 21.03 (18.35) 23.33 (15.09) 2.3 (3.3)
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different contours made by the centers (yellow) in com-
parison with the expert delineation (blue). At the same 
time, based on the mHD index comparison, the lowest 
agreements were found for the PCM, CE, and prophy-
lactic PTV with a mHD ± SD of 22.9 ± 17.28, 18.20 ± 4.2 
and 16.05 ± 6.03. The organs who showed the highest 
variation in terms of SD, across all institutions at final 
submissions for the mDSI are the CE, G and supraglot-
tic larynx (SL) with a SD of around 0.2 and for the mHD: 
PCM (17.28), CE (9.64) and the Spinal cord PRV (8.79). 
Figure  2 displays the box plots of the mDSI and mHD 
indexes for each volume at the final submission.
At the final evaluation all dose constraints of the 
EORTC 1420 protocol were fulfilled without greater 
difficulty (Table  3). The organ at risk which was closest 
to the given dose requirements was the thyroid gland 
with a Dmean of 23 Gy (Protocol: Dmean < 25 Gy). The 
brainstem PRV was the most variable structure in terms 
of dose distribution with a mean  Dmax of 20  Gy (range: 
4.6–37  Gy) followed by the EOC with a  Dmean of 27.5 
(range: 18.4–35.8 Gy). Figure 3 shows the Dose variations 
regarding each RT volume.
Discussion
Thirty-five European institutions with in total 81 submit-
ted benchmarks participated in this ancillary analysis 
inside an ongoing EORTC Head and neck trial. Hence, 
to our knowledge this represents the largest BC analysis 
in current literature among Head and neck quality assur-
ance programs. This analysis followed the suggestions on 
reporting items for studies on IOV in volume delineation 
made by Vinod et al. [22].
First, we could affirm that the major source of proto-
col variations relies on the delineation process, be it for 
OARs (53%) or target volumes (35%). This can be sim-
ply explained by a greater number of non-routing DARS 
required by the protocol. Considering each volume sep-
arately, pPTV was by far the major cause of rejection 
(24%). Several reasons could be identified as for example 
non protocol conformal selection of prophylactic lymph 
node regions, inadequate boundaries and inclusion of 
natural barriers inside the clinical target volume (CTV). 
These results are in par with the two other BC analysis 
inside the EORTC Head and neck Trials portfolio: In the 
EORTC 22071-26071 BC analysis, a trial evaluating the 
benefit of Panitumumab in addition to adjuvant chemo-
radiotherapy in locally advanced resected HNC revealed 
that 43.5% of the 23 submitted cases presented major 
protocol deviation on target volume delineations (GTVs, 
CTVs and PTVs) [11]. Additionally, Christiaens et  al. 
published the EORTC 1219-Dahanca-29 BC analysis, an 
intergroup trial evaluating the influence of Nimorazole in 
patients with locally advanced head and neck cancer [23]. 
This work was done on 34 delineation BCs submitted by 
19 centers. The authors reported a similar rejection rate 
of 63% (65% in our analysis). Furthermore, incorrect 
selection of prophylactic lymph node regions, were the 
major cause of rejection. This highlights the fact that elec-
tive nodal irradiation in terms of selection of LN regions 
and their corresponding delimitations still represents a 
major source of heterogeneity despite current guidelines. 
With regard to OAR delineations, in the EORTC 1219 BC 
trial, absence of contours represented the major reason 
for first refusal (10%). In our study, PCM was the princi-
pal reason for rejection. Only a minority (12%) of varia-
tions were due to planning issues.
After RTQA intervention, no notable difference could 
be detected in terms of mDSI. In the opposite, regard-
ing mHD, an improvement in almost all volumes was 
observed. More precisely, in 5 out of 12 volumes, the 
mHD difference was even more than 10  mm. In the 
EORTC 1219 trial an improvement from the first to final 
submission in mDSI and mHD values was found to be 
increased for the prophylactic CTV (mDSI: 0.09 mHD: 
−  11.6). On the other hand, the therapeutic CTV vol-
ume was only marginally improved (mDSI: 0.01; mHD: 
0.4  mm). These findings were in par with our results 
highlighting an improvement for the prophylactic tar-
get volume of—10.6 (SD 17) in mHD and 0.07 in mDSI. 
Identically, the changes in therapeutic volume metrics 
were negligible. Furthermore, regarding the PCM, mHD 
increased by—10.6 (SD 17). Their seems to be a relation-
ship between the rejected OARs and IOV improvement. 
Table 2 Mean DSI and HD indexes for the final volumes
Final volume DSI (SD) HD (SD)
Planning organ‑at‑risk volume of the brain‑
stem
0.79 (0.12) 8.05 (2.59)
Cervical esophagus 0.44 (0.22) 18.20 (9.64)
Contralateral parotid 0.81 (0.05) 12.94 (5.27)
Cricoid pharyngeal inlet 0.33 (0.16) 12.93 (6.12)
Contralateral sub‑mandibular gland 0.83 (0.06) 7.02 (4.28)
Extended oral cavity‑PTV 0.86 (0.07) 12.14 (6.13)
Glottis 0.56 (0.20) 8.81 (4.28)
Ipsilateral parotid 0.81 (0.04) 11.71 (4.24)
Mandible 0.92 (0.02) 7.52 (7.47)
Pharyngeal constrictor muscles 0.62 (0.08) 22.86 (17.28)
Prophylactic PTV 0.79 (0.06) 16.05 (6.03)
Therapeutic PTV 0.74 (0.10) 9.35 (3.47)
Planning organ‑at‑risk volume of the spinal 
cord
0.77 (0.13) 12.52 (8.79)
Supraglottic larynx 0.66 (0.16) 11.58 (6.05)
Thyroid gland 0.86 (0.02) 4.36 (1.20)
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Fig. 1 Graphic representation on axial, sagittal and coronal planes of interobserver variation between institutions concerning the cricopharyngeal 
inlet (a), cervical esophagus (b), supraglottic larynx (c), therapeutic PTV (d) and glottis (e). The reference delineation is represented in blue outline
Page 6 of 10Stelmes et al. Radiat Oncol           (2021) 16:81 
Fig. 2 Boxplots of the Dice conformity Index and Hausdorff Index for each RT volume at final submission
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In particular prophylactic PTV and pharyngeal con-
strictor muscles, both figured among the most frequent 
causes of BC rejection and had their mHD improved by 
more than 10 mm. In the counterpart, therapeutic PTV 
improved after RTQA intervention but with a smaller 
margin even if represented by a relatively high rejection 
Table 3 Mean institutional dose distributions and dose requirements of the EORTC 1420 protocol for the different volumes
Volumes Mean institutional doses (SD) Dose requirements 
given by the EORTC 1420 
Protocol
Planning organ‑at‑risk volume of the brainstem Dmax = 19.96 (9.12) Dmax < 35 Gy
Cervical esophagus Dmean = 14.75 (5.43) Dmean < 30 Gy
Contralateral parotid Dmean = 5.53 (1.79) Dmean < 5–10 Gy
Cricoid pharyngeal inlet D2% = 47.34 (6.98) D2% < 66 Gy
Contralateral sub‑mandibular gland Dmean = 7.82 (1.67) Dmean < 10 Gy
Extended oral cavity‑PTV Dmean = 27.54 (4.66) Dmean < 30–35 Gy
Glottis Dmean = 16.26 (3.56) Dmean < 20 Gy
Ipsilateral parotid Dmean = 25.60 (5.83) Dmean < 30–35 Gy
Mandible D2% = 56.92 (4.59) D2% < 66 Gy
Pharyngeal constrictor muscles Dmean = 33.75 (3.95) Dmean < 30–40 Gy
Prophylactic PTV D95% = 52.91 (0.81) D95% > 51.7 Gy
Therapeutic PTV D95% = 63.89 Gy (1.04) D95% > 62.7 Gy
Planning organ‑at‑risk volume of the spinal cord Dmax = 36.95 (4.05) Dmax < 40 Gy
Supraglottic larynx Dmean = 23.56 (4.90) Dmean < 45–50 Gy
Thyroid gland Dmean = 23.26 (2.05) Dmean < 25 Gy
Fig. 3 Dose variations received by RT volumes based on the protocol dose contraints
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rate. This is probably because changes in volume resub-
missions are smaller.
The apparent discrepancy between both indexes 
relies on their different nature: The Dice coefficient is a 
volume-based metric and therefore commonly used to 
measure reproducibility. In the opposite, mHD index 
is part of the spatial distance-based metrics and conse-
quently makes it especially interesting for highlighting 
the largest mismatch between the consensus contours 
and the submitted contours [24]. Therefore mHD is often 
more sensitive for benchmarking, simply by the fact that 
most critical sources of fluctuance, from an anatomical 
point of view derive from the upper and lower anatomi-
cal boundaries [25]. This criterion is most critical for lon-
gitudinal and narrow organs at risk as for example the CE 
and PCM and therefore mHD index is best fit to evaluate 
such discrepancies.
In addition, final mDSI and mHD metrics varied 
between 0.33 (cricopharyngeal inlet)—0.92 (mandi-
ble) and 22.86 (pharyngeal constrictor muscles)—4.36 
(thyroid gland) respectively. By choosing an aleatory 
threshold of 0.7 for mDSI and 15 mm for mHD, the CE-
CPI-PCM-SL and glottis are in the high risk IOV group 
for mDSI variability as the PCM-CE and prophylac-
tic PTV are in the high IOV group for mHD variability. 
Furthermore, after excluding one single outlier of PCM, 
CE had the highest dispersion around the mean for both 
metrics (mDSI: 0.22; mHD: 9.64). In conclusion, these 
outcomes reinforce our hypothesis that new non-routine 
OARs in addition to the elective lymph node stations are 
at highest risk for IOV. Another hypothesis is that, due to 
low experience in non-routine OAR contouring, partici-
pating institutions tend to overestimate the true size of 
the organs.
In addition, in the EORTC 1219 DAHANCA BC analy-
sis, the highest disagreement was observed for the larynx 
(mDSI/mHD 0.46 and 32.9) and oral cavity (mDSI/mHD: 
0.49 and 19.08). This difference is increased in confront 
to our findings [(supraglottic larynx: mDSI/mHD: 0.66 
and 11.58) and (oral cavity: mDSI/mHD: 0.86 and 12.14)]. 
This difference can be mainly explained by the fact that 
clear guidelines on organ at risk contouring were absent 
at that time.
Regarding the potential impact of volume IOV on 
dose distribution, no such evaluation could be made in 
our dataset as plans were created only in case volume 
acceptability was granted by the reviewers. However, 
in the EORTC 22071-26071 trial, the authors showed 
no statistically significant correlation between the PTV 
volume and the ability to meet parotid dose constraints 
(p > 0.20), neither between parotid contour acceptability 
nor meeting constraints (p = 0.17). Therefore, we hypoth-
esize a low impact of IOV on dosimetry variations in 
case protocol requirements are fulfilled. Evaluating the 
potential impact of volume IOV on clinical outcomes, 
a review of several BC analysis realized among EORTC 
trials could not reveal any correlation between protocol 
conformal benchmarking and clinical results for a given 
trial [26].
Concerning the dose evaluation, no major difficulties 
were notified in reaching the given dose-constraints. 
Brainstem PRV was the most variable OAR. This find-
ing is unsurprising as the brainstem tolerance in this 
protocol is far below the clinically recognized tolerance. 
Therefore, the participating institutions made no effort to 
optimize the dose to the brainstem.
Some limitations of this study should be mentioned: 
More accurate methods have been introduced since to 
estimate and reduce IOV, as the STAPLE ( simultaneous 
truth and performance level estimation) algorithm [27]. 
This method is a validated formula which considers a col-
lection of segmentations and estimates the ground truth 
based on the performance level by each segmentation. 
In addition, novel strategies for implementing OAR con-
touring guidelines at a national scale [28], visual atlases 
[29] and the use of digital platforms [30] have been pro-
posed to further reduce IOV. Even more recently, artifi-
cial intelligence systems have been studied to simplify the 
workflow of radiotherapy [31]. In particular deep learning 
contouring (DLC) for Head and neck OARs were devel-
oped with satisfying preliminary results [32]. Indeed, DSI 
as mean and max dose difference were found to be signif-
icantly improved in 19 out of 22 OARs compared to the 
atlas based contouring (ABAS) by 0.15, 3.1 Gy and 3.3 Gy 
respectively[33]. The impact on dose distributions after 
Benchmark resubmissions could not be analyzed due to 
the internal process of planning once the volumes have 
been already been approved.
In conclusion, for this specific HNC trial with dys-
phagia as the primary endpoint and therefore critical 
relevance of correct delineation of not routinely deline-
ated OARs, benchmarking was an effective tool to avoid 
protocol deviation and reduce IOV. On the other hand, in 
times of global increase of research costs, financing aca-
demic trials becomes a real challenge. We therefore rec-
ommend for future benchmark analyses an evaluation on 
the impact on dosimetry and clinical outcome as part of 
every trial initiation package [34].
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